01 October 2010
Response to chemotherapy in a case of gastric adenocarcinoma producing granulocyte colony-stimulating factor
Hiroki MoriABCDEF, Tomoyoshi ShibuyaABCDEF, Taro OsadaABCDEF, Tomohiro KodaniB, Yoshie HigashiharaB, Nobuko SerizawaB, Junko KatoCD, Akihito NagaharaEF, Tatsuo OgiharaAE, Sumio WatanabeADEMed Sci Monit 2010; 16(10): CS119-123 :: ID: 881183
Abstract
Background: Little is known about the patient characteristics and tumor characteristics associated with a high level of granulocyte colony-stimulating factor (G-CSF) and leukocytosis. Moreover, the prognosis of G-CSF-producing gastric cancer has been extremely poor.
Case Report: A 72-year-old man presented with fatigue and body weight loss. Laboratory testing showed pronounced leukocytosis (white blood cell count, 34900×106/L). Bone marrow aspiration biopsy excluded leukemia and metastatic leukemoid reaction. G-CSF-producing cancer was suspected as the cause of the abnormally elevated serum G-CSF level (293 pg/ml). Gastrointestinal endoscopy showed type 3 gastric cancer, and the biopsy specimens were histologically proven to include moderately to well differentiated adenocarcinoma with positive expression of G-CSF. Abdominal computed tomography showed a lymph node lesion and multiple hepatic metastatic lesions. This patient was diagnosed as having stage IV gastric cancer that produced G-CSF. We treated the patient with 3 chemotherapy regimens, and he survived for almost 2 years after diagnosis.
Conclusions: The possibility of a G-CSF-producing tumor should be investigated in patients who present with severe leukocytosis in the absence of infection. This unusual gastric cancer should be treated as soon as possible after diagnosis.
Keywords: Liver Neoplasms - secondary, Leukocytosis - etiology, Granulocyte Colony-Stimulating Factor - therapeutic use, Bone Marrow - pathology, Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma - metabolism
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952